ProtecTing Low-Risk Prostate Cancer

The landmark Prostate Testing for Cancer and Treatment (ProtecT) study was published in September 2016 (1). This is the first randomized trial to answer the question of which treatment among surgery, radiation therapy, and active surveillance is best for low-risk prostate cancer. The fact that the authors were able to perform and complete this study deserves immense credit.

http://ift.tt/2w6zZUI